Rosuvastatin: A highly efficacious statin for the treatment of dyslipidaemia

Expert Opinion on Investigational Drugs

Volumn 11, Issue 1, 2002, Pages 125-141

  Davidson, M H ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Dyslipidaemia; Statins

Indexed keywords

ALPRENOLOL; AMITRIPTYLINE; ATORVASTATIN; CERIVASTATIN; CYTOCHROME P450 3A4; DIAZEPAM; DICLOFENAC; FENOFIBRATE; FLUINDOSTATIN; HEXOBARBITAL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; ITRACONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEPHENYTOIN; METHYLPHENOBARBITAL; MEVINOLIN; NORDAZEPAM; OMEPRAZOLE; PHENYTOIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATIN; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DYSLIPIDEMIA; ENANTIOMER; HUMAN; HYDROPHILICITY; MALE; NONHUMAN; PLASMA HALF LIFE; RAT; SIDE EFFECT; CLINICAL TRIAL; COMPARATIVE STUDY; HALF LIFE TIME; HYPERLIPIDEMIA; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS; FLUOROBENZENES; HALF-LIFE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0036139706     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.1.125     Document Type: Article

References (28)

1. Executive Summary of the third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
2. The lipid treatment assessment project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
3. New statins and new doses of older statins
4. Pharmacological properties of ZD 4522 - A new HMG CoA reductase inhibitor
5. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C
6. Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissue of the rat
7. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells
8. Single-and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522
9. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor ZD4522 after AM and PM dosing in healthy subjects
10. Erythromycin has no clinically relevant effect on the pharmacokinetics of rosuvastatin
11. Fluconazole has no clinically relevant effect on the pharmacokinetics of rosuvastatin
12. Lack of pharmacokinetic interaction between rosuvastatin and fenofibrate in healthy volunteers
13. Itraconazole produces modest increases in rosuvastatin plasma concentrations
14. Does differing metabolism by cytochrome P450 have clinical importance?
15. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
16. ZD4522 is superior to atorvastatin in decreasing low density lipoprotein cholesterol and increasing high density lipoprotein cholesterol in patients with Type IIa or IIb hypercholesterolemia
17. Long-term efficacy and safety of rosuvastatin: Results of a 52-week comparator-controlled trial versus atorvastatin
18. ZD4522 is superior to pravastatin and simvastatin in reducing low density lipoprotein cholesterol, enabling more hypercholesterolemic patients to achieve target low density lipoprotein cholesterol guidelines
19. Long-term efficacy and safety of rosuvastatin: Results of a 52-week comparator-controlled trial versus pravastatin and simvastatin
20. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia
21. Effects of rosuvastatin on serum lipids and lipid subfractions in patients with hypertriglyceridemia
22. Comparison of statins in hypertriglyceridemia
23. Rosuvastatin alone and in combination with fenofibrate in hyperlipidaemic patients with Type 2 diabetes
24. Beneficial effects of combination therapy with rosuvastatin and extended-release niacin in patients with mixed dyslipidemia
25. Rosuvastatin alone produces similar lipid benefits compared with rosuvastatin plus cholestyramine in patients with primary hypercholesterolemia
26. A review of the safety profile of rosuvastatin in an international Phase II/III clinical trial programme
27. The evaluation of atherosclerotic outcomes with rosuvastatin therapy (EARTH) study: A study in high-risk patients with below average LDL-c levels
28. Study design for a randomized, double-blind trial to assess the effect of 24 months of dosing with rosuvastatin on progression of carotid artery atheroma in moderately hypercholesterolemic patients with asymptomatic carotid stenosis